GAO Drug Pricing Report Finds Faster Growth In AWP Than Retail Price
This article was originally published in The Pink Sheet Daily
Executive SummaryThe trend could have implications for Medicaid and third-party payors that base their reimbursement for drugs on average wholesale price.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Stephen Hahn will go before the Senate health committee less than three weeks after being nominated. Pink Sheet's historical charts illustrate how a long wait and a quick hearing could mean a rapid confirmation.